{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:33:25Z","timestamp":1793223205284,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015620","name":"Center for Innovations in Quality, Effectiveness and Safety","doi-asserted-by":"publisher","award":["13-413"],"award-info":[{"award-number":["13-413"]}],"id":[{"id":"10.13039\/100015620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019592","name":"Veterans Administration Medical Center, Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["IIR 19-045"],"award-info":[{"award-number":["IIR 19-045"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","cghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cgh.2024.06.049","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T06:56:33Z","timestamp":1723618593000},"page":"386-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["The Cost of Inflammatory Bowel Disease Care: How to Make it Sustainable"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-5139","authenticated-orcid":false,"given":"Johan","family":"Burisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Claytor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Ken","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilaad G.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2024.06.049_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/ecco-jcc\/jjac138","article-title":"The incidence and prevalence of paediatric- and adult-onset inflammatory bowel disease in Denmark during a 37-year period: a nationwide cohort study (1980-2017)","volume":"17","author":"Dorn-Rasmussen","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.049_bib3","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.14309\/ajg.0000000000002687","article-title":"Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC). forecasting the incidence and prevalence of inflammatory bowel disease: a Canadian nationwide analysis","volume":"119","author":"Coward","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib4","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib5","series-title":"Early biologic treatment versus conventional treatment for the management of Crohn\u2019s disease: a review of comparative clinical effectiveness and cost-effectiveness","author":"Thompson","year":"2019"},{"key":"10.1016\/j.cgh.2024.06.049_bib6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib7","first-page":"S23","article-title":"The 2023 impact of inflammatory bowel disease in canada: direct health system and medication costs","volume":"6","author":"Kuenzig","year":"2023","journal-title":"J\u00a0Can Assoc Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib8","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/curroncol29040223","article-title":"The economic burden of cancer in Canada from a societal perspective","volume":"29","author":"Garaszczuk","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cgh.2024.06.049_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cgh.2016.09.012","article-title":"Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases","volume":"15","author":"Limsrivilai","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib10","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.049_bib11","first-page":"S1","article-title":"The 2023 Impact of Inflammatory Bowel Disease in Canada: executive summary","volume":"6","author":"Windsor","year":"2023","journal-title":"J\u00a0Can Assoc Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.gastro.2006.05.052","article-title":"European Collaborative Study on Inflammatory Bowel Disease. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation","volume":"131","author":"Odes","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.049_bib13","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1053\/j.gastro.2008.09.012","article-title":"Direct health care costs of Crohn\u2019s disease and ulcerative colitis in US children and adults","volume":"135","author":"Kappelman","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.049_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2468-1253(20)30012-1","article-title":"Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study","volume":"5","author":"Burisch","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.14309\/ajg.0000000000000503","article-title":"Longitudinal trends in the direct costs and health care utilization ascribable to inflammatory bowel disease in the biologic era: results from a Canadian population-based analysis","volume":"115","author":"Targownik","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib16","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.14309\/ajg.0000000000000750","article-title":"Home infliximab infusions are associated with suboptimal outcomes without cost savings in inflammatory bowel diseases","volume":"115","author":"Giese-Kim","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib17","first-page":"99","article-title":"A\u00a0primer on brand-name prescription drug reimbursement in the United States","volume":"30","author":"Hernandez","year":"2024","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.cgh.2024.06.049_bib18","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1377\/hlthaff.2023.00250","article-title":"Changes in net prices and spending for pharmaceuticals after the introduction of new therapeutic competition, 2011-19","volume":"42","author":"Dickson","year":"2023","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.cgh.2024.06.049_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2468-1253(19)30013-5","article-title":"Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development","volume":"4","author":"King","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12859-021-04083-x","article-title":"Classifying chest CT images as COVID-19 positive\/negative using a convolutional neural network ensemble model and uniform experimental design method","volume":"22","author":"Chen","year":"2021","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.cgh.2024.06.049_bib21","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s10620-021-07200-1","article-title":"Systematic review and meta-analysis: risk of hospitalization in patients with ulcerative colitis and Crohn\u2019s disease in population-based cohort studies","volume":"67","author":"Tsai","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2024.06.049_bib22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/gutjnl-2019-318440","article-title":"Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study","volume":"69","author":"Murthy","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.06.049_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1377\/hlthaff.2023.01360","article-title":"National health care spending in 2022: growth similar to prepandemic rates","volume":"43","author":"Hartman","year":"2024","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.cgh.2024.06.049_bib24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2468-1253(17)30248-0","article-title":"Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn\u2019s disease: a randomised controlled, open-label, multicentre trial","volume":"2","author":"Ponsioen","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib25","first-page":"S16","article-title":"The 2023 Impact of Inflammatory Bowel Disease in Canada: indirect (individual and societal) and direct out-of-pocket costs","volume":"6","author":"Kuenzig","year":"2023","journal-title":"J\u00a0Can Assoc Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib26","article-title":"Costs of missed work among employed people with inflammatory bowel disease: a cross-sectional population-representative study","volume":"7","author":"Kuenzig","year":"2022","journal-title":"Int J Popul Data Sci"},{"key":"10.1016\/j.cgh.2024.06.049_bib27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/apt.15889","article-title":"Healthcare use, work loss and total costs in incident and prevalent Crohn\u2019s disease and ulcerative colitis: results from a nationwide study in Sweden","volume":"52","author":"Khalili","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.049_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jpeds.2022.04.014","article-title":"High impact of pediatric inflammatory bowel disease on caregivers\u2019 work productivity and daily activities: an\u00a0international prospective study","volume":"246","author":"Klomberg","year":"2022","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cgh.2024.06.049_bib29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/00365521.2021.1908416","article-title":"Inflammatory bowel disease-related economic costs due to presenteeism and absenteeism","volume":"56","author":"Rankala","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ibd\/izaa179","article-title":"Variations in health care utilization patterns among inflammatory bowel disease patients at risk for high medical service utilization enrolled in high deductible health plans","volume":"27","author":"Berinstein","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.049_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819827692","article-title":"Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010","volume":"12","author":"Aniwan","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.gastro.2020.08.064","article-title":"Effects of race and ethnicity on diagnosis and management of inflammatory bowel diseases","volume":"160","author":"Barnes","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.049_bib33","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/ibd\/izaa266","article-title":"National estimates of financial hardship from medical bills and cost-related medication nonadherence in patients with inflammatory bowel diseases in the United States","volume":"27","author":"Nguyen","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.049_bib34","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/MIB.0000000000000418","article-title":"Patterns and predictors of long-term nonuse of medical therapy among persons with inflammatory bowel disease","volume":"21","author":"Melesse","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.049_bib35","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.14309\/ajg.0000000000000794","article-title":"Social determinants of outcomes in inflammatory bowel disease","volume":"115","author":"Bernstein","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MAJ.0b013e31816a5c06","article-title":"Crohn\u2019s disease in an African-American population","volume":"336","author":"Jackson","year":"2008","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.cgh.2024.06.049_bib37","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/ajg.2010.202","article-title":"Racial disparities in utilization of specialist care and medications in inflammatory bowel disease","volume":"105","author":"Nguyen","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib38","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.puhe.2015.01.029","article-title":"Apparent discrimination in the provision of biologic therapy to patients with Crohn\u2019s disease according to ethnicity","volume":"129","author":"Farrukh","year":"2015","journal-title":"Public Health"},{"key":"10.1016\/j.cgh.2024.06.049_bib39","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cgh.2018.02.015","article-title":"Annual burden and costs of hospitalization for high-need, high-cost patients with chronic gastrointestinal and liver diseases","volume":"16","author":"Nguyen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib40","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/ibd\/izz060","article-title":"Increased healthcare utilization by patients with inflammatory bowel disease covered by Medicaid at a tertiary care center","volume":"25","author":"Axelrad","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.049_bib41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/MIB.0000000000000994","article-title":"The Crohn\u2019s and Colitis Foundation of America survey of inflammatory bowel disease patient health care access","volume":"23","author":"Rubin","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.049_bib42","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.cgh.2020.05.056","article-title":"Prevalence and effects of food insecurity and social support on financial toxicity in and healthcare use by patients with inflammatory bowel diseases","volume":"19","author":"Nguyen","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","article-title":"\u2018Equity in access to treatment of rheumatoid arthritis in Europe.\u2019 Inequities in access to biologic and synthetic DMARDs across 46 European countries","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2024.06.049_bib44","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.3748\/wjg.v23.i34.6294","article-title":"Access to biologicals in Crohn\u2019s disease in ten European countries","volume":"23","author":"P\u00e9ntek","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S2468-1253(23)00284-4","article-title":"Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America","volume":"9","author":"Balderramo","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib46","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/s12913-019-4815-5","article-title":"Access to specialty healthcare in urban versus rural US populations: a systematic literature review","volume":"19","author":"Cyr","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.cgh.2024.06.049_bib47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/ibd\/izy276","article-title":"Quality of care in patients with inflammatory bowel disease","volume":"25","author":"Jackson","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.049_bib48","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/imj.14187","article-title":"Crohn\u2019s & Colitis Australia inflammatory bowel disease audit: measuring the quality of care in Australia","volume":"49","author":"Massuger","year":"2019","journal-title":"Intern Med J"},{"key":"10.1016\/j.cgh.2024.06.049_bib49","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/jgh3.12631","article-title":"Assessing effectiveness and patient perceptions of a novel electronic medical record for the management of inflammatory bowel disease","volume":"5","author":"Kaazan","year":"2021","journal-title":"JGH Open"},{"key":"10.1016\/j.cgh.2024.06.049_bib50","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1572-0241.2005.40849.x","article-title":"Are patients with inflammatory bowel disease receiving optimal care?","volume":"100","author":"Reddy","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib51","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/00365521.2017.1278785","article-title":"Clinicians\u2019 adherence to international guidelines in the clinical care of adults with inflammatory bowel disease","volume":"52","author":"Jackson","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib52","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/apt.12929","article-title":"The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn\u2019s disease","volume":"40","author":"Schoepfer","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.049_bib53","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002851","article-title":"Insurer-mandated medication utilization barriers are associated with decreased insurance satisfaction and adverse clinical outcomes: an Inflammatory Bowel Disease Partners Survey","author":"Constant","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib54","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/MIB.0000000000001153","article-title":"Variations in health insurance policies regarding biologic therapy use in inflammatory bowel disease","volume":"23","author":"Yadav","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.049_bib55","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.049_bib56","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.06.049_bib57","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(23)00062-6","article-title":"Managing inflammatory bowel disease: what to do when the best is unaffordable?","volume":"8","author":"Banerjee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib58","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A\u00a0biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib59","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002720","article-title":"Insurance companies\u2019 poor adherence to guidelines for moderate-to-severe ulcerative colitis\/Crohn\u2019s disease management","author":"Anderson","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.049_bib60","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ecco-jcc\/jjz003","article-title":"The evolution of health care utilisation and costs for inflammatory bowel disease over ten years","volume":"13","author":"Pillai","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.049_bib61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ecco-jcc\/jjz096","article-title":"Direct and indirect costs of inflammatory bowel disease: ten years of follow-up in a Danish population-based inception cohort","volume":"14","author":"Lo","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.049_bib62","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/jamainternmed.2020.3188","article-title":"Uptake of infliximab biosimilars among the Medicare population","volume":"180","author":"Chen","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cgh.2024.06.049_bib63","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jamainternmed.2020.0338","article-title":"Shift from adalimumab originator to biosimilars in Denmark","volume":"180","author":"Jensen","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cgh.2024.06.049_bib64","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jama.2023.25389","article-title":"Biologic patent thickets and terminal disclaimers","volume":"331","author":"Tu","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2024.06.049_bib65","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.17379","article-title":"Trends in list prices, net prices, and discounts for originator biologics facing biosimilar competition","volume":"2","author":"San-Juan-Rodriguez","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cgh.2024.06.049_bib66","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamadermatol.2020.2685","article-title":"Trends in list and net prices of self-administered systemic psoriasis therapies manufactured by US-based pharmaceutical companies","volume":"156","author":"Ferris","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib67","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/art.41277","article-title":"Biosimilar uptake in academic and Veterans Health Administration settings: influence of institutional incentives","volume":"72","author":"Baker","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib68","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.37765\/ajmc.2022.89297","article-title":"Provider and patient knowledge gaps on biosimilars: insights from surveys","volume":"28","author":"Gibofsky","year":"2022","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.cgh.2024.06.049_bib69","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2147\/PPA.S104891","article-title":"Patient attitudes and understanding about biosimilars: an international cross-sectional survey","volume":"10","author":"Jacobs","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.cgh.2024.06.049_bib70","series-title":"How lawmakers can achieve savings from biosimilars: lessons from Kaiser Permanente","author":"Lang","year":"2023"},{"key":"10.1016\/j.cgh.2024.06.049_bib71","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1007\/s11606-022-07670-7","article-title":"Uptake and competition among biosimilar biological products in the US Medicare fee-for-service population","volume":"37","author":"Kozlowski","year":"2022","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.cgh.2024.06.049_bib72","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.cgh.2018.04.007","article-title":"Reduced unplanned care and disease activity and increased quality of life after patient enrollment in an inflammatory bowel disease medical home","volume":"16","author":"Regueiro","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib73","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.cgh.2017.02.037","article-title":"White Paper AGA: the impact of mental and psychosocial factors on the care of patients with inflammatory bowel disease","volume":"15","author":"Szigethy","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib74","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11894-017-0561-1","article-title":"Making a medical home for IBD patients","volume":"19","author":"Kosinski","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.cgh.2024.06.049_bib75","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.cgh.2021.08.034","article-title":"A\u00a0care coordination intervention improves symptoms but not charges in high-risk patients with inflammatory bowel disease","volume":"20","author":"Berinstein","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(20)31723-6","article-title":"Sa1761. An interdisciplinary care program for recently diagnosed inflammatory bowel disease patients is associated with increased clinical remission rates and lower steroid use","volume":"158","author":"Ungaro","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.049_bib77","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.crohns.2011.08.019","article-title":"A\u00a0chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease","volume":"6","author":"Sack","year":"2012","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.049_bib78","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.cgh.2021.08.048","article-title":"Interventions to decrease unplanned healthcare utilization and improve quality of care in adults with inflammatory bowel disease: a systematic review","volume":"20","author":"Fudman","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib79","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(17)31327-2","article-title":"Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial","volume":"390","author":"Jong","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.06.049_bib80","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cgh.2020.04.038","article-title":"Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial","volume":"18","author":"Jong","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.049_bib81","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.50211","article-title":"Estimated indirect cost savings of using telehealth among nonelderly patients with cancer","volume":"6","author":"Patel","year":"2023","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524007298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524007298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T01:23:11Z","timestamp":1739323391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356524007298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1542356524007298"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2024.06.049","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Cost of Inflammatory Bowel Disease Care: How to Make it Sustainable","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2024.06.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}